Macrocylux

Gadoteric acid, the active ingredient in Macrocylux, is a gadolinium‑based contrast agent presented as a sterile solution for intravenous use. It is employed to enhance magnetic resonance imaging by improving the visibility of vascular structures and central nervous system tissues during diagnostic examinations.

GNH USA supplies Macrocylux as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, imaging centres and clinics worldwide. The company adheres to stringent quality standards and provides regulatory‑approved batches to meet global diagnostic imaging needs through reliable logistics.

Macrocylux, a gadolinium‑based contrast agent, is used in magnetic resonance imaging to improve visualization of specific anatomical areas. - Central nervous system imaging: provides enhanced delineation of brain lesions and spinal cord pathology. - Vascular MRI (angiography): improves arterial lumen definition and vessel wall assessment. - Perfusion studies: facilitates accurate measurement of tissue perfusion dynamics. - Whole‑body MRI screening: aids in detecting metastatic disease by highlighting abnormal tissue contrast.

Adverse reactions to Macrocylux may vary in frequency and severity.

Common Side Effects: - Nausea: mild to moderate feeling of stomach upset. - Headache: transient headache occurring shortly after injection. - Injection site discomfort: pain or warmth at the infusion site. - Metallic taste: brief sensation of metal in the mouth. - Dizziness: mild vertigo that resolves quickly. - Warm sensation: feeling of heat spreading through the body.

Serious or Rare Side Effects: - Anaphylactic reaction: severe allergy requiring immediate medical intervention. - Nephrogenic systemic fibrosis (NSF): rare fibrotic disorder in patients with severe renal impairment. - Severe hypotension: marked drop in blood pressure post‑administration. - Cardiac arrest: extremely rare but life‑threatening event. - Severe skin rash: extensive erythema or urticaria requiring treatment.

Prior to using Macrocylux, clinicians should consider several safety measures. - Renal function assessment: evaluate glomerular filtration rate to identify patients at risk of NSF. - Pregnancy and lactation: use only if clearly necessary, as safety data are limited. - Allergy history: screen for prior reactions to gadolinium‑based contrast agents. - Hydration: ensure adequate patient hydration before and after the procedure. - Dosage adjustment: consider reduced dose in patients with severe renal impairment. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Macrocylux may interact with other medicines, affecting safety or efficacy.

Major Interactions (Avoid): - Renal toxic agents (e.g., high‑dose aminoglycosides): may increase risk of nephrotoxicity. - Concurrent gadolinium‑based contrast agents: cumulative gadolinium load can raise NSF risk. - Iron chelators: may destabilize the gadolinium chelate.

Moderate Interactions (Monitor Closely): - Beta‑blockers: may mask contrast‑induced hypotension. - Diuretics: can alter renal clearance of the agent. - Metformin: hold before and after administration in patients with impaired renal function to prevent lactic acidosis.